Management

Anders holds a Bachelor of Economics in business administration from Webster University, Genève.

Anders has been the CEO of several companies within the biotech and financial sector. For 10 years, Anders held the position as CEO of Isofol Medical AB (publ), developing the cancer drug candidate arfolitixorin.

Holds 322,480 shares in Epicyt Pharma AB through Albonja AB.

Miguel is MD and PhD.

Miguel is a pharmaceutical Industry executive with more than 20 years of experience in leading operational and strategic functions at all stages clinical development from early stages of academia, via industry first-in-man translation to launch and commercialization. Experience in large organizations as well as in start-up environment.

Lars is a Medical Doctor and PhD. Professor at the Dept of Surgery, Sahlgrenska Academy, University of Gothenburg.

Lars has studied the functions of surgical techniques for over 30 years and has during the last 15 years been focused on weight-reducing surgery. He is together with Associate Professor Ville Wallenius the inventor behind Epicyt Pharma AB.

Other assignments

Founder and former board member of several companies, eg. Vicore Pharma AB. He is CEO in BENF AB.

Holds 256,000 shares in Epicyt Pharma AB through BENF AB.

Bengt received his MSc Pharm from Uppsala University. Bengt is a serial entrepreneur and investor in the life science field and through Linc AB an investor in Epicyt.

Other assignments

Bengt is chairman of Linc AB and Knil AB, board member Animal Probiotics Sweden AB, Cronhamn Invest AB, Livland Skog AB, Medivir Aktiebolag, nWise AB, Part Production Sweden AB, Reison Medical AB, Sedana Medical AB, Stille AB, Swevet AB and Swevet Holding AB. Board member and deputy board member in small subsidiaries of the above companies or small family-owned companies.

Holds 1,216,192 shares in Epicyt Pharma AB through ownership in Linc AB.